← Return to PRRT has been approved by the FDA Jan 26, 2018, as expected

Discussion

PRRT has been approved by the FDA Jan 26, 2018, as expected

Neuroendocrine Tumors (NETs) | Last Active: Feb 11, 2023 | Replies (15)
Comment receiving replies
@tomewilson

Hi Mark,

I am not familiar with the term ‘Type 2A’. Please help me. Is this what you mean in the context of staging: Stage IIA describes a tumor larger than 4 cm but 5 cm or less in size that has not spread to the nearby lymph nodes.

Since I’m not sure of the reference to type 2A, I can’t answer the minimum threshold question.

Regarding Afinitor being used to control growth, the answer is yes. In my wife's case she experienced progressive liver disease and so has been on Afinitor for over 4 1/2 years - well past its usual efficacy. Her next treatment may well be PRRT. Sequencing of treatments is very important. You msy have already told me this, but make dure you are seeing a recognized NETs specialist in a high volume NETs center.

Please follow up with any questions.

Jump to this post

Replies to "Hi Mark, I am not familiar with the term ‘Type 2A’. Please help me. Is this..."
markmark007 | @markmark007 | Feb 9, 2023

Hello Tom: - many thanks
The term "somatostatin receptor type 2A":
I read about this in your post dated Aug. 1,2018. I understand that was a long time ago - I was intrigued by the content.
My wife's recent Ga-68 scan revealed additional lesions on the liver as well as additional NET's in hip and lower spine locations. I was wondering if the provider needs to have the staining as you mentioned in the above referenced post. I'm not expecting specific recommendations for her but just any general comments based on your experiences are appreciated.
You also mentioned Dr. Halfdanarson - we have watched several of his videos.
Note: my wife is being treated @ Fred Hutch - Seattle (formerly SCCA) by Dr. Chorian. Perhaps Fred Hutch is not quite on the same level for NET treatment as other cancer centers are.
Thanks again,

Mark

VIEW AND REPLY